Sunday 18 October 2026
Export ESLA’s income statement to Excel — free account
Estrella Immunopharma, Inc.
ESLA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 66.7% and free cash flow fell 329.2%, each against the same quarter a year earlier.
0.43
0.11
−20.37%
Follow ESLA
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 148.05% | 373.21% | 255.59% | 199.78% |
+8 more TTM periods Free account |
|
| (416.74%) | (434.36%) | (413.55%) | (250.19%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
134.74% | 195.73% | 110.09% | 80.10% | |
Free Cash Flow per Share |
(0.22) | (0.19) | (0.05) | 0.05 | |
Free Cash Flow |
(9.38) | (8.02) | (1.79) | 2.02 | |
| Other line items | |||||
Cash ROIC |
128.81% | 239.84% | 19.88% | (24.63%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.94 | 0.61 | 0.14 | (0.22) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.22) | (0.19) | (0.05) | 0.05 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates